These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 31285776)

  • 1. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
    Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
    Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
    Zhang C; Yuan W; Wu Y; Wan X; Gong Y
    Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
    Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
    Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.
    Zhao Z; Li Y; Liu H; Jain A; Patel PV; Cheng K
    Sci Adv; 2020 Jul; 6(29):eabb0616. PubMed ID: 32832636
    [No Abstract]   [Full Text] [Related]  

  • 6. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
    Park K; Lee MY; Kim KS; Hahn SK
    Biomaterials; 2010 Jul; 31(19):5258-65. PubMed ID: 20378167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
    Lu ZX; Liu LT; Qi XR
    Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
    Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
    [No Abstract]   [Full Text] [Related]  

  • 9. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes.
    Kim SH; Lee SH; Tian H; Chen X; Park TG
    J Drug Target; 2009 May; 17(4):311-7. PubMed ID: 19242850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
    Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
    J Control Release; 2008 Jul; 129(2):107-16. PubMed ID: 18486981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-monomer derived linear-like PEI-co-PEG for siRNA delivery and silencing.
    Tsai LR; Chen MH; Chien CT; Chen MK; Lin FS; Lin KM; Hwu YK; Yang CS; Lin SY
    Biomaterials; 2011 May; 32(14):3647-53. PubMed ID: 21324524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
    Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
    Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
    Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
    J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
    Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
    Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
    Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
    J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
    Song Y; Tang C; Yin C
    Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.
    Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
    J Control Release; 2006 Nov; 116(2):123-9. PubMed ID: 16831481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.